Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist

European Journal of Pharmacology

Volumn 412, Issue 3, 2001, Pages 213-221

  Baurand, Anthony ^a   Raboisson, Pierre ^b   Freund, Monique ^a   Léon, Catherine ^a   Cazenave, Jean Pierre ^a   Bourguignon, Jean Jacques ^b   Gachet, Christian ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b CNRS   (France)

Author keywords

Antiplatelet drug; MRS2179 (N6 methyl 2 dexyadenosine 3 ,5 bisphosphat e); P2Y1 receptor; Platelet aggregation; Thrombosis

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; ADENYLATE CYCLASE; N6 METHYL 2' DEOXYADENOSINE 3',5' BIPHOSPHATE; PURINE P2Y RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLEEDING TIME; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; COMPETITIVE INHIBITION; DRUG EFFECT; ENZYME INHIBITION; HEMOSTASIS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADENOSINE DIPHOSPHATE; ALPROSTADIL; ANIMALS; APYRASE; BLOOD PLATELETS; CALCIUM; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RADIOLIGAND ASSAY; RATS; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION; THIONUCLEOTIDES;

EID: 0035793347     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00733-6     Document Type: Article

References (23)

1. 1 and P2cyc receptors
2. 1 receptor
3. 6-methyl 2′-deoxyadenosine 3′-5′-bisphosphate
4. ADP receptors and clinical bleeding disorders
5. L'agrégation plaquettaire: Outil d'investigation clinique et d'étude pharmacologique - Méthodologie
6. Molecular basis for ADP-induced platelet activation: I. Evidence for three distinct ADP receptors on human platelets
7. 1-deficient mice
8. 1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors
9. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets
10. Purinoreceptors on blood platelets: Further pharmacological and clinical evidence to suggest the presence of two ADP receptors
11. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel
12. 1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
13. 1 receptor is necessary for adenosine-5′-diphosphate-induced platelet aggregation
14. The adhesiveness of human blood platelets in vitro
15. Pharmacology of AR-C69931MX and related compounds: From pharmacological tools to clinical trials
16. FPL66096: A novel, highly potent and selective antagonist at human platelet P2T-purinoreceptors
17. Coactivation of two different G-protein-coupled receptors is essential for ADP-induced platelet aggregation
18. 1 receptor null mice
19. The P2Y1 receptor is normal in a patient presenting a severe deficiency of ADP-induced platelet aggregation
20. 1 receptor in tissue factor-induced thrombin independent acute thromboembolism
21. ADP plays a key role in thrombogenesis in rats
22. LIGAND: A versatile computerized approach for characterization of ligand-binding systems
23. Pharmacology of ticlopidine and clopidogrel